STOCK TITAN

Titan Medical Announces Benchmark Electronics, Inc. Purported to Terminate Agreement

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Titan Medical Inc. (TSX: TMD; OTC: TMDIF) faces manufacturing and supply agreement termination with Benchmark Electronics, Inc.
Positive
  • None.
Negative
  • None.

TORONTO, Ontario, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has purported to terminate the agreement. Titan did not receive delivery from Benchmark of manufactured Enos Surgical System units and disputes that Benchmark has grounds for the termination. Titan has rejected Benchmark’s allegation that Titan breached the agreement.

About Titan Medical

Titan Medical Inc. (TSX: TMD; OTC: TMDIF), a medical technology company headquartered in Toronto, Ontario, has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the Company evaluating new opportunities to further develop and license its intellectual property.

These forward-looking statements reflect management’s current beliefs with respect to future events and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, the Company’s ability to retain key personnel; its ability to execute on its business plans and strategies; its ability to continue to license some or all its intellectual property to third parties and receive any material consideration and other factors listed in the “Risk Factors” section of the Company’s Annual Information Form for the fiscal year ended December 31, 2022 (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.

Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and the Company has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly qualified by the foregoing cautionary statements.

Contact
Chien Huang
Chief Financial Officer
investors@titanmedicalinc.com

###


FAQ

What is the latest announcement from Titan Medical Inc. (TSX: TMD; OTC: TMDIF)?

Titan Medical Inc. announced that Benchmark Electronics, Inc. has purported to terminate the manufacturing and supply agreement for Titan’s Enos Surgical System.

What is the ticker symbol for Titan Medical Inc.?

The ticker symbol for Titan Medical Inc. is TMD on the TSX and TMDIF on the OTC.

What is the nature of the dispute between Titan Medical Inc. and Benchmark Electronics, Inc.?

Titan disputes Benchmark's grounds for the termination and rejects the allegation of breaching the agreement.

How does the termination of the manufacturing and supply agreement impact Titan Medical Inc. (TSX: TMD; OTC: TMDIF)?

The termination may affect the production and supply of Titan’s Enos Surgical System, potentially impacting the company's operations and financial performance.

What are the implications of Benchmark Electronics, Inc. terminating the agreement for Titan Medical Inc. (TSX: TMD; OTC: TMDIF) shareholders?

The termination may raise concerns for shareholders regarding the company's manufacturing capabilities and future prospects, potentially impacting the stock performance.

How does the termination of the agreement with Benchmark Electronics, Inc. reflect on Titan Medical Inc.'s (TSX: TMD; OTC: TMDIF) business development?

The termination raises questions about Titan's ability to secure reliable manufacturing partnerships and execute its business plans effectively.

TITAN MEDICAL INC ORD

OTC:TMDIF

TMDIF Rankings

TMDIF Latest News

TMDIF Stock Data

4.10M
71.8%
1.33%
Medical Devices
Healthcare
Link
United States of America
Toronto